Reeves Daniel B, Litchford Morgan, Fish Carolyn S, Farrell-Sherman Anna, Poindexter Makayla, Ahmed Nashwa, Cassidy Noah A J, Neary Jillian, Wamalwa Dalton, Langat Agnes, Chebet Daisy, Moraa Hellen, Antar Annukka A R, Slyker Jennifer, Benki-Nugent Sarah, Cohn Lillian B, Schiffer Joshua T, Overbaugh Julie, John-Stewart Grace, Lehman Dara A
Vaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Global Health, University of Washington, Seattle, Washington, United States of America.
PLoS Pathog. 2025 Apr 4;21(4):e1013003. doi: 10.1371/journal.ppat.1013003. eCollection 2025 Apr.
To inform cure in children living with HIV (CWH), we elucidated the dynamics and mechanisms underlying HIV persistence during antiretroviral therapy (ART). In 120 Kenyan CWH who initiated ART between 1-12 months of age, 55 had durable viral load suppression, and 65 experienced ART interruptions. We measured plasma HIV RNA levels, CD4+ T cell count, and levels of intact and defective HIV DNA proviruses via the cross-subtype intact proviral DNA assay (CS-IPDA). By modeling data from the durably suppressed subset, we found that during early ART (year 0-1 on ART), plasma RNA levels decayed rapidly and biphasically and intact and defective HIV DNA decayed with mean 3 and 9 month half-lives, respectively. After viral suppression was achieved (years 1-8 on ART), intact HIV DNA decay slowed to a mean 22 month half-life, whilst defective HIV DNA no longer decayed. In five CWH, we found individual CD4+ TCRβ clones wax and wane, but average kinetics resembled those of defective DNA and CD4 count, suggesting that differential decay of intact HIV DNA arises from selective pressures overlaying normal CD4+ T cell kinetics. Finally, by modeling HIV RNA and DNA in CWH with treatment interruptions, we linked temporary viremia to transient rises in HIV DNA, but long-term intact reservoirs were not strongly influenced, suggesting brief treatment interruptions may not significantly increase HIV reservoirs in children.
为了指导对感染艾滋病毒儿童(CWH)的治疗,我们阐明了抗逆转录病毒疗法(ART)期间艾滋病毒持续存在的动态过程和机制。在120名1至12个月大开始接受ART治疗的肯尼亚CWH中,55名实现了持久的病毒载量抑制,65名经历了ART中断。我们通过跨亚型完整前病毒DNA检测法(CS - IPDA)测量了血浆艾滋病毒RNA水平、CD4 + T细胞计数以及完整和缺陷艾滋病毒DNA前病毒的水平。通过对持久抑制亚组的数据进行建模,我们发现,在ART治疗早期(治疗的第0 - 1年),血浆RNA水平迅速呈双相衰减,完整和缺陷艾滋病毒DNA的衰减半衰期分别为3个月和9个月。在实现病毒抑制后(治疗的第1 - 8年),完整艾滋病毒DNA的衰减减缓至平均22个月的半衰期,而缺陷艾滋病毒DNA不再衰减。在5名CWH中,我们发现单个CD4 + TCRβ克隆数量有增减,但平均动力学类似于缺陷DNA和CD4计数的动力学,这表明完整艾滋病毒DNA的差异衰减源于叠加在正常CD4 + T细胞动力学上的选择性压力。最后,通过对有治疗中断情况的CWH中的艾滋病毒RNA和DNA进行建模,我们将暂时的病毒血症与艾滋病毒DNA的短暂升高联系起来,但长期完整储存库并未受到强烈影响,这表明短暂的治疗中断可能不会显著增加儿童体内的艾滋病毒储存库。